Delivery of therapeutic proteins

Journal of Pharmaceutical Sciences

Volumn 99, Issue 6, 2010, Pages 2557-2575

  Pisal, Dipak S ^a   Kosloski, Matthew P ^a   Balu Iyer, Sathy V ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Hyperglycosylation; Liposomes; PEGylation; Poly(lactic glycolic) acid; Protein delivery

Indexed keywords

ARGININE DERIVATIVE; ASPARAGINASE MACROGOL; CALCITONIN; CERTOLIZUMAB PEGOL; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 2; INTERLEUKIN 6; MACROGOL; METHIONINE GAMMA LYASE; PEG ARGININE DEAMINASE; PEG CALCITONIN; PEG CDP 791; PEG GRANULOCYTE COLONY STIMULATING FACTOR; PEG INTERLEUKIN 2; PEG INTERLEUKIN 6; PEG METHIONINASE; PEG SUPEROXIDE DISMUTASE; PEG URICASE; PEGADEMASE; PEGAPTANIB; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGINTERFERON BETA1A; PEGVISOMANT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URATE OXIDASE;

ACROMEGALY; ANEMIA; BIOTECHNOLOGY; CLINICAL TRIAL; CROHN DISEASE; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; GLYCOSYLATION; HEPATITIS C; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; NEUTROPENIA; NONHUMAN; PROTEIN TRANSPORT; RETINA MACULA DEGENERATION; RHEUMATOID ARTHRITIS; SEVERE COMBINED IMMUNODEFICIENCY; SHORT SURVEY;

EID: 77951571813     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22054     Document Type: Short Survey

References (165)

1. Tang L, Persky AM, Hochhaus G, Meibohm B. 2004. Pharmacokinetic aspects of biotechnology products. J Pharm Sci 93:2184-2204.
2. Malik NN. 2008. Drug discovery: Past, present and future. Drug Discov Today 13:909-912.
3. Soderquist RG, Milligan ED, Sloane EM, Harrison JA, Douvas KK, Potter JM, Hughes TS, Chavez RA, Johnson K, Watkins LR, Mahoney MJ. 2009. PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution. J Biomed Mater Res A 91:719-729.
4. Almeida AJ, Souto E. 2007. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 59:478-490. (Pubitemid 47260710)
5. Banakar UV. 1997. Advances and opportunities in delivery of therapeutic proteins and peptides. J Biomater Appl 11:377-429. (Pubitemid 127622909)
6. Veronese FM, Harris JM. 2002. Introduction and overview of peptide and protein pegylation. Adv Drug Deliv Rev 54:453-456.
7. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF. 1977. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 252:3582-3586. (Pubitemid 8116088)
8. Abuchowski A, van Es T, Palczuk NC, Davis FF. 1977. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 252:3578-3581. (Pubitemid 8116087)
9. Harris JM, Chess RB. 2003. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214-221.
10. Harris JM, Martin NE, Modi M. 2001. Pegylation: A novel process for modifying pharmacokinetics. Clin Pharmacokinet 40:539-551. (Pubitemid 32738660)
11. Kozlowski A, Harris JM. 2001. Improvements in protein PEGylation: Pegylated interferons for treatment of hepatitis C. J Control Release 72:217-224. (Pubitemid 32522359)
12. MacEwen EG, Rosenthal R, Matus R, Viau AT, Abuchowski A. 1987. A preliminary study on the evaluation of asparaginase. Polyethylene glycol conjugate against canine malignant lymphoma. Cancer 59:2011-2015.
13. Pyatak PS, Abuchowski A, Davis FF. 1980. Preparation of a polyethylene glycol: Superoxide dismutase adduct, and an examination of its blood circulation life and anti-inflammatory activity. Res Commun Chem Pathol Pharmacol 29:113-127. (Pubitemid 10082336)
14. Pasut G, Veronese FM. 2009. PEGylation for improving the effectiveness of therapeutic biomolecules. Drug Discov (Barc) 45:687-695.
15. Roberts MJ, Harris JM. 1998. Attachment of degradable poly(ethylene glycol) to proteins has the potential to increase therapeutic efficacy. J Pharm Sci 87:1440-1445. (Pubitemid 28514154)
16. Roberts MJ, Bentley MD, Harris JM. 2002. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54:459-476.
17. Veronese FM. 2001. Peptide and protein PEGylation: A review of problems and solutions. Biomaterials 22:405-417.
18. Jain A, Jain SK. 2008. PEGylation: An approach for drug delivery. A review. Crit Rev Ther Drug Carrier Syst 25:403-447.
19. Monfardini C, Schiavon O, Caliceti P, Morpurgo M, Harris JM, Veronese FM. 1995. A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug Chem 6:62-69.
20. Goodson RJ, Katre NV. 1990. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology (NY) 8:343-346. (Pubitemid 20138305)
21. Yokoyama M, Okano T, Sakurai Y, Kikuchi A, Ohsako N, Nagasaki Y, Kataoka K. 1992. Synthesis of poly(ethylene oxide) with heterobifunctional reactive groups at its terminals by an anionic initiator. Bioconjug Chem 3:275-276.
22. Kinstler OBGNE, Farrar CE, DePrince RB. 1999. N-terminally chemically modified protein compositions and methods, United States Patent 5985265.
23. Kinstler O, Molineux G, Treuheit M, Ladd D, Gegg C. 2002. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 54:477-485.
24. Kinstler OBD, Lauren S, Paige A, Hamburger J, Treuheit M. 1995. Characterization and stability of N-terminally pegylated Rhg-CSF. Pharm Res 13:996-1002. (Pubitemid 26258997)
25. Acharya A, Sussman L, Manning J. 1983. Schiff base adducts of glyceraldehyde with hemoglobin. Differences in the Amadori rearrangement at the alpha-amino groups. J Biol Chem 258: 2296-2302.
26. Hu T, Prabhakaran M, Acharya SA, Manjula BN. 2005. Influence of the chemistry of conjugation of poly(ethylene glycol) to Hb on the oxygen-binding and solution properties of the PEG-Hb conjugate. Biochem J 392:555-564. (Pubitemid 43022735)
27. Sato H. 2002. Enzymatic procedure for site-specific pegylation of proteins. Adv Drug Deliv Rev 54:487-504. (Pubitemid 34615545)
28. Chen T, Small DA, Wu L-Q, Rubloff GW, Ghodssi R, Vazquez- Duhalt R, Bentley WE, Payne GF. 2003. Nature-inspired creation of protein - Polysaccharide conjugate and its subsequent assembly onto a patterned surface. Langmuir 19:9382-9386.
29. Veronese FM, Pasut G. 2005. PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451-1458. (Pubitemid 41483874)
30. Bailon P, Berthold W. 1998. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm Sci Technol Today 1:352-356.
31. Knauf M, Bell D, Hirtzer P, Luo Z, Young J, Katre N. 1988. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem 263:15064-15070.
32. Caliceti P, Veronese FM. 2003. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 55:1261-1277. (Pubitemid 37464561)
33. Bhat R, Timasheff SN. 1992. Steric exclusion is the principal source of the preferential hydration of proteins in the presence of polyethylene glycols. Protein Sci 1:1133-1143. (Pubitemid 23016427)
34. Bendele A, Seely J, Richey C, Sennello G, Shopp G. 1998. Short communication: Renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci 42: 152-157. (Pubitemid 28211143)
35. Young MA, Malavalli A, Winslow N, Vandegriff KD, Winslow RM. 2007. Toxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys. Transl Res 149:333-342. (Pubitemid 46818159)
36. Delgado C, Francis GE, Fisher D. 1992. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 9:249-304.
37. Nucci ML, Shorr R, Abuchowski A. 1991 The therapeutic value of poly(ethylene glycol)-modified proteins. Adv Drug Deliv Rev 6:133-151.
38. Rajan RS, Li T, Aras M, Sloey C, Sutherland W, Arai H, Briddell R, Kinstler O, Lueras AM, Zhang Y, Yeghnazar H, Treuheit M, Brems DN. 2006. Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study. Protein Sci 15:1063-1075.
39. Muller AF, Kopchick JJ, Flyvbjerg A, van der Lely AJ. 2004. Growth Hormone Receptor Antagonists. J Clin Endocrinol Metab 89:1503-1511.
40. Fishburn CS. 2008. The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics. J Pharm Sci 97:4167-4183.
41. Veronese FM, Mero A, Caboi F, Sergi M, Marongiu C, Pasut G. 2007. Site-specific pegylation of G-CSF by reversible denaturation. Bioconjug Chem 18:1824-1830. (Pubitemid 350219980)
42. Wang X, Ishida T, Kiwada H. 2007. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release 119:236-244. (Pubitemid 46759557)
43. Hershfield MS. 1995. PEG-ADA replacement therapy for adenosine deaminase deficiency: An update after 8.5 years. Clin Immunol Immunopathol 76:S228-S232.
44. Fontana A, Spolaore B, Mero A, Veronese FM. 2008. Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Adv Drug Deliv Rev 60:13-28. (Pubitemid 350181164)
45. Pasut G, Veronese FM. 2007. Polymer-drug conjugation, recent achievements and general strategies. Prog Polym Sci 32:933-961. (Pubitemid 47198290)
46. Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, Cremona F, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA, Ng C, Curley SA. 2004. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: Results from phase I/II studies. J Clin Oncol 22:1815-1822. (Pubitemid 41095171)
47. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT, Ensor CM, Prestayko AW, Holtsberg FW, Bomalaski JS, Clark MA, Savaraj N, Feun LG, Logan TF. 2005. Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies. J Clin Oncol 23:7660-7668. (Pubitemid 46291831)
48. Pasut G, Veronese FM. 2009. PEG conjugates in clinical development or use as anticancer agents: An overview. Adv Drug Del Rev 61:1177-1188.
49. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. 2000. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132:296-305. (Pubitemid 30106261)
50. Tsutsumi Y, Tsunoda S, Kamada H, Kihira T, Kaneda Y, Ohsugi Y, Mayumi T. 1997. PEGylation of interleukin-6 effectively increases its thrombopoietic potency. Thromb Haemost 77:168-173. (Pubitemid 27064988)
51. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK, Hepatitis Interventional Therapy Group. 2001. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34:395-403.
52. Torchilin VP. 2005. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145-160.
53. Yamamoto Y, Tsutsumi Y, Yoshioka Y, Nishibata T, Kobayashi K, Okamoto T, Mukai Y, Shimizu T, Nakagawa S, Nagata S, Mayumi T. 2003. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol 21:546-552. (Pubitemid 36532020)
54. Zhai Y, Zhao Y, Lei J, Su Z, Ma G. 2009. Enhanced circulation half-life of site-specific PEGylated rhG-CSF: Optimization of PEG molecular weight. J Biotechnol 142:259-266.
55. Morpurgo M, Veronese FM, Kachensky D, Harris JM. 1996. Preparation of characterization of poly(ethylene glycol) vinyl sulfone. Bioconjug Chem 7:363-368. (Pubitemid 126639671)
56. Sinclair AM, Elliott S. 2005. Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci 94:1626-1635. (Pubitemid 41360859)
57. Medzihradszky KF, Besman MJ, Burlingame AL. 1997. Structural characterization of site-specific N-glycosylation of recombinant human factor VIII by reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry. Anal Chem 69:3986-3994. (Pubitemid 127493231)
58. Narhi LO, Arakawa T, Aoki KH, Elmore R, Rohde MF, Boone T, Strickland TW. 1991. The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem 266:23022-23026. (Pubitemid 21908754)
59. Schmidt FR. 2004. Recombinant expression systems in the pharmaceutical industry. Appl Microbiol Biotechnol 65:363-372. (Pubitemid 39281088)
60. Kosloski MP, Miclea RD, Balu-Iyer SV. 2009. Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII. AAPS J 11:424-431.
61. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. 2003. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 9:38-49. (Pubitemid 36511631)
62. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. 1993. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 81:2925-2935.
63. Jefferis R. 2009. Recombinant antibody therapeutics: The impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 30:356-362.
64. Gregoriadis G, Jain S, Papaioannou I, Laing P. 2005. Improving the therapeutic efficacy of peptides and proteins: A role for polysialic acids. Int J Pharm 300:125-130. (Pubitemid 41112174)
65. Varki NM, Varki A. 2007. Diversity in cell surface sialic acid presentations: Implications for biology and disease. Lab Invest 87:851-857. (Pubitemid 47267816)
66. Muhlenhoff M, Eckhardt M, Gerardy-Schahn R. 1998. Polysialic acid: Three-dimensional structure, biosynthesis and function. Curr Opin Struct Biol 8:558-564. (Pubitemid 28486380)
67. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. 2005. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122:107-118. (Pubitemid 40977944)
68. Pless DD, Lennarz WJ. 1977. Enzymatic conversion of proteins to glycoproteins. Proc Natl Acad Sci USA 74:134-138.
69. Bause E, Lehle L. 1979. Enzymatic N-glycosylation and O-glycosylation of synthetic peptide acceptors by dolichol-linked sugar derivatives in yeast. Eur J Biochem 101:531-540. (Pubitemid 10151308)
70. Bordo D, Argos P. 1991. Suggestions for "safe" residue substitutions in site-directed mutagenesis. J Mol Biol 217:721-729.
71. Egrie JC, Browne JK. 2001. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16:3-13. (Pubitemid 32591159)
72. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. 2006. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 8:R12.
73. Fernandes AI, Gregoriadis G. 1997. Polysialylated asparaginase: Preparation, activity and pharmacokinetics. Biochim Biophys Acta 1341:26-34. (Pubitemid 27357031)
74. Fernandes AI, Gregoriadis G. 2001. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: Implication in its pharmacokinetics. Int J Pharm 217:215-224. (Pubitemid 32268647)
75. Jain S, Hreczuk-Hirst DH, McCormack B, Mital M, Epenetos A, Laing P, Gregoriadis G. 2003. Polysialylated insulin: Synthesis, characterization and biological activity in vivo. Biochim Biophys Acta 1622:42-49. (Pubitemid 36776349)
76. Evelyn DL, Ryan JH, Joseph PB. 2004. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645-2668.
77. Constantinou A, Epenetos AA, Hreczuk-Hirst D, Jain S, Deonarain MP. 2008. Modulation of antibody pharmacokinetics by chemical polysialylation. Bioconjug Chem 19:643-650. (Pubitemid 351431395)
78. Constantinou A, Epenetos AA, Hreczuk-Hirst D, Jain S, Wright M, Chester KA, Deonarain MP. 2009. Site-specific polysialylation of an antitumor single-chain Fv fragment. Bioconjug Chem 20:924-931.
79. Egrie JC, Browne JK. 2002. Development and characterization of darbepoetin alfa. Oncology (Williston Park) 16:13-22.
80. 2009. Aranesp (R) Rx. Physicians' Desk Reference 63 ed. Montvale, New Jersey: Thomson PDR.
81. McKoy JM, Stonecash RE, Cournoyer D, Rossert J, Nissenson AR, Raisch DW, Casadevall N, Bennett CL. 2008. Epoetin-associated pure red cell aplasia: Past, present, and future considerations. Transfusion 48:1754-1762.
82. Lipoxen. 2009. http://www.lipoxen.com/pipeline/polyxenproduct-pipeline. aspx accessed in July 2009.
83. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. 1994. Biodegradable long-circulating polymeric nanospheres. Science 263:1600-1603.
84. Richardson TP, Murphy WL, Mooney DJ. 2001. Polymeric delivery of proteins and plasmid DNA for tissue engineering and gene therapy. Crit Rev Eukaryot Gene Expr 11:47-58.
85. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. 2008. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release 125:193-209.
86. Nishiyama N, Kataoka K. 2006. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther 112:630-648. (Pubitemid 44592613)
87. Kost J, Langer R. 2001. Responsive polymeric delivery systems. Adv Drug Deliv Rev 46:125-148.
88. Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, Levy- Nissenbaum E, Radovic-Moreno AF, Langer R, Farokhzad OC. 2007. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28:869-876. (Pubitemid 44667020)
89. Esmaeili F, Ghahremani MH, Esmaeili B, Khoshayand MR, Atyabi F, Dinarvand R. 2008. PLGA nanoparticles of different surface properties: Preparation and evaluation of their body distribution. Int J Pharm 349:249-255. (Pubitemid 350299701)
90. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. 2001. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70:1-20. (Pubitemid 32144788)
91. Cai Q, Shi G, Bei J, Wang S. 2003. Enzymatic degradation behavior and mechanism of Poly(lactide-co-glycolide) foams by trypsin. Biomaterials 24:629-638. (Pubitemid 35346392)
92. Freitas S, Merkle HP, Gander B. 2005. Microencapsulation by solvent extraction/evaporation: Reviewing the state of the art of microsphere preparation process technology. J Control Release 102:313-332.
93. Bittner B, Morlock M, Koll H, Winter G, Kissel T. 1998. Recombinant human erythropoietin (rhEPO) loaded poly(lactide- co-glycolide) microspheres: Influence of the encapsulation technique and polymer purity on microsphere characteristics. Eur J Pharm Biopharm 45:295-305.
94. Li Y-P, Pei Y-Y, Zhang X-Y, Gu Z-H, Zhou Z-H, Yuan W-F, Zhou J-J, Zhu J-H, Gao X-J. 2001. PEGylated PLGA nanoparticles as protein carriers: Synthesis, preparation and biodistribution in rats. J Control Release 71:203-211.
95. Han K, Lee K-D, Gao Z-G, Park J-S. 2001. Preparation and evaluation of poly(-lactic acid) microspheres containing rhEGF for chronic gastric ulcer healing. J Control Release 75:259-269.
96. Johansen P, Moon L, Tamber H, Merkle HP, Gander B, Sesardic D. 1999. Immunogenicity of single-dose diphtheria vaccines based on PLA/PLGA microspheres in guinea pigs. Vaccine 18:209-215.
97. Sinha VR, Trehan A. 2003. Biodegradable microspheres for protein delivery. J Control Release 90:261-280.
98. Bouchard A, Jovanovic N, de Boer AH, Martín Á, Jiskoot W, Crommelin DJA, Hofland GW, Witkamp G-J. 2008. Effect of the spraying conditions and nozzle design on the shape and size distribution of particles obtained with supercritical fluid drying. Eur J Pharm Biopharm 70:389-401.
99. Jovanović N, Bouchard A, Hofland GW, Witkamp G-J, Crommelin DJA, Jiskoot W. 2004. Stabilization of proteins in dry powder formulations using supercritical fluid technology. Pharm Res 21:1955-1969.
100. Choi S-W, Kim J-H. 2007. Design of surface-modified poly(d,l-lactide-co- glycolide) nanoparticles for targeted drug delivery to bone. J Control Release 122:24-30.
101. Singh S, Webster DC, Singh J. 2007. Thermosensitive polymers: Synthesis, characterization, and delivery of proteins. Int J Pharm 341:68-77.
102. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. 2008. Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J Control Release 125:193-209.
103. Carrasquillo KG, Stanley AM, Aponte-Carro JC, De Jésus P, Costantino HR, Bosques CJ, Griebenow K. 2001. Non-aqueous encapsulation of excipient-stabilized spray-freeze dried BSA into poly(lactide-co-glycolide) microspheres results in release of native protein. J Control Release 76:199-208.
104. Ravi Kumar MNV, Bakowsky U, Lehr CM. 2004. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials 25:1771-1777.
105. Cleland JL. 1998. Development of stable formulations for PLGA/PLA microsphere vaccines. Res Immunol 149:45-47.
106. Chan JM, Zhang L, Yuet KP, Liao G, Rhee J-W, Langer R, Farokhzad OC. 2009. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 30:1627-1634.
107. Jeong B, Lee KM, Gutowska A, An YH. 2002. Thermogelling biodegradable copolymer aqueous solutions for injectable protein delivery and tissue engineering. Biomacromolecules 3:865-868.
108. Johnson OL, Cleland JL, Lee HJ, Charnis M, Duenas E, Jaworowicz W, Shepard D, Shahzamani A, Jones AJ, Putney SD. 1996. A month-long effect from a single injection of microencapsulated human growth hormone. Nat Med 2:795-799.
109. Yuksel E, Weinfeld AB, Cleek R, Waugh JM, Jensen J, Boutros S, Shenaq SM, Spira M. 2000. De novo adipose tissue generation through long-term, local delivery of insulin and insulin-like growth factor-1 by PLGA/PEG microspheres in an in vivo rat model: A novel concept and capability. Plast Reconstr Surg 105:1721-1729.
110. Duncan R. 2003. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2:347-360.
111. Heller J. Polymers for controlled parenteral delivery of peptides and proteins. Adv Drug Deliv Rev 10:163-204.
112. Chan YP, Meyrueix R, Kravtzoff R, Nicolas F, Lundstrom K. 2007. Review on Medusa: A polymer-based sustained release technology for protein and peptide drugs. Expert Opin Drug. Deliv 4:441-451.
113. Flamel 2009. http://www.flamel.com/techAndProd/medusa.shtml.
114. PharmaIN 2009. http://www.pharmain.com/PrdcPplnPGCGLP1.html.
115. GMBH FKD. 2008. Hesylation Technology. AAPS National Biotechnology Conference, Toronto, Canada abstract.
116. Chonn A, Cullis PR. 1995. Recent advances in liposomal drug-delivery systems. Curr Opin Biotechnol 6:698-708.
117. Porter CJH, Wasan KM, Constantinides P. 2008. Lipid-based systems for the enhanced delivery of poorly water soluble drugs. Adv Drug Deliv Rev 60:615-616.
118. Constantinides PP, Wasan KM. 2004. Advances in lipid-based drug solubilization and targeting. Adv Drug Deliv Rev 56:1239-1240.
119. Rawat M, Singh D, Saraf S, Saraf S. 2008. Lipid carriers: A versatile delivery vehicle for proteins and peptides. Yakugaku Zasshi 128:269-280.
120. Miclea RD, Varma PR, Peng A, Balu-Iyer SV. 2007. Development and characterization of lipidic cochleate containing recombinant factor VIII. Biochim Biophys Acta 1768:2890-2898.
121. Davis SS. 2004. Coming of age of lipid-based drug delivery systems. Adv Drug Deliv Rev 56:1241-1242.
122. Martins S, Sarmento B, Ferreira DC, Souto EB. 2007. Lipid-based colloidal carriers for peptide and protein delivery - Liposomes versus lipid nanoparticles. Int J Nanomed 2: 595-607.
123. Ramani K, Miclea RD, Purohit VS, Mager DE, Straubinger RM, Balu-Iyer SV. 2008. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. J Pharm Sci 97:1386-1398.
124. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. 1999. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691-744.
125. Torchilin VP, Trubetskoy VS. 1995. Which polymers can make nanoparticulate drug carriers long-circulating? Adv Drug Deliv Rev 16:141-155.
126. Maeda H, Sawa T, Konno T. 2001. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74: 47-61.
127. Reulen SWA, Brusselaars WWT, Langereis S, Mulder WJM, Breurken M, Merkx M. 2007. Protein-Liposome conjugates using cysteine-lipids and native chemical ligation. Bioconjug Chem 18:590-596.
128. Szoka FC. 2004. Review of Liposomes: Edited by Vladimir P. Torchilin, Volkmar Weissig, Oxford University Press, Oxford, 2003, 424 pp.
129. J Control Release 96:353-353
130. Mastrobattista E, Koning GA, van Bloois L, Filipe AC, Jiskoot W, Storm G. 2002. Functional characterization of an endosome- disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J Biol Chem 277:27135-27143.
131. Bendas G, Krause A, Schmidt R, Vogel J, Ulrich R. 1998. Selectins as new targets for immunoliposome-mediated drug delivery: A potential way of anti-inflammatory therapy. Pharmaceutica Acta Helvetiae 73:19-26.
132. Moghimi SM, Szebeni J. 2003. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42:463-478.
133. Maruyama K, Takizawa T, Takahashi N, Tagawa T, Nagaike K, Iwatsuru M. 1997. Targeting efficiency of PEG-immunoliposome- conjugated antibodies at PEG terminals. Adv Drug Deliv Rev 24:235-242.
134. Gabizon AA. 1995. Liposome circulation time and tumor targeting: Implications for cancer chemotherapy. Adv Drug Deliv Rev 16:285-294.
135. Benson HA, Namjoshi S. 2008. Proteins and peptides: Strategies for delivery to and across the skin. J Pharm Sci 97:3591-3610.
136. Ramani K, Purohit VS, Miclea RD, Middaugh CR, Balasubramanian SV. 2005. Lipid binding region (2303- 2332) is involved in aggregation of recombinant human FVIII (rFVIII). J Pharm Sci 94:1288-1299.
137. Oussoren C, Zuidema J, Crommelin DJA, Storm G. 1997. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: II. Influence of liposomal size, lipid composition and lipid dose. Biochim Biophys Acta 1328:261-272.
138. Doktorovova S, Souto EB. 2009. Nanostructured lipid carrier-based hydrogel formulations for drug delivery: A comprehensive review. Expert Opin Drug Deliv 6:165-176.
139. Chen M-L. 2008. Lipid excipients and delivery systems for pharmaceutical development: A regulatory perspective. Adv Drug Deliv Rev 60:768-777.
140. U.S., Department of Health and Human Services FaDA, Center for Drug Evaluation and Research. Draft guidance for industry: Liposome drug products - chemistry, manufacturing and controls; human pharmacokinetics and bioavailability; and labeling documentation. Rockville, MD: Office of Training and Communications. Division of Drug Information, HFD-240, p (Internet): http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070570.pdf.
141. Stanimirovic DB, Markovic M, Micic DV, Spatz M, Mrsulja BB. 1994. Liposome-entrapped superoxide dismutase reduces ischemia/reperfusion 'oxidative stress' in gerbil brain. Neurochem Res 19:1473-1478.
142. Luisa Corvo M, Jorge JCS, van't Hof R, Cruz MEM, Crommelin DJA, Storm G. 2002. Superoxide dismutase entrapped in long-circulating liposomes: Formulation design and therapeutic activity in rat adjuvant arthritis. Biochim Biophys Acta 1564:227-236.
143. Gaspar MM, Perez-Soler R, Cruz ME. 1996. Biological characterization of L-asparaginase liposomal formulations. Cancer Chemother Pharmacol 38:373-377.
144. Jorge JC, Perez-Soler R, Morais JG, Cruz ME. 1994. Liposomal palmitoyl-L-asparaginase: Characterization and biological activity. Cancer Chemother Pharmacol 34:230-234.
145. Heeremans JL, Prevost R, Bekkers ME, Los P, Emeis JJ, Kluft C, Crommelin DJ. 1995. Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: A comparison with free t-PA. Thromb Haemost 73:488-494.
146. Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Hirano K. 2001. A novel and simple type of liposome carrier for recombinant interleukin-2. J Pharm Pharmacol 53:295-302.
147. Kanaoka E, Takahashi K, Yoshikawa T, Jizomoto H, Nishihara Y, Uchida N, Maekawa R, Hirano K. 2002. A significant enhancement of therapeutic effect against hepatic metastases of M5076 in mice by a liposomal interleukin-2 (mixture). J Control Release 82:183-187.
148. Opanasopit P, Sakai M, Nishikawa M, Kawakami S, Yamashita F, Hashida M. 2002. Inhibition of liver metastasis by targeting of immunomodulators using mannosylated liposome carriers. J Control Release 80:283-294.
149. Kisel MA, Kulik LN, Tsybovsky IS, Vlasov AP, Vorob'yov MS, Kholodova EA, Zabarovskaya ZV. 2001. Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: Studies in the rat. Int J Pharm 216:105-114.
150. Kim A, Yun MO, Oh YK, Ahn WS, Kim CK. 1999. Pharmacodynamics of insulin in polyethylene glycol-coated liposomes. Int J Pharm 180:75-81.
151. Hoffmann PR, Kench JA, Vondracek A, Kruk E, Daleke DL, Jordan M, Marrack P, Henson PM, Fadok VA. 2005. Interaction between Phosphatidylserine and the Phosphatidylserine Receptor Inhibits Immune Responses In Vivo. J Immunol 174:1393-1404.
152. Purohit VS, Ramani K, Sarkar R, Kazazian HH, Jr., Balasubramanian SV. 2005. Lower inhibitor development in Hemophilia A mice following administration of recombinant factor VIII -O-phospho-L-serine complex. J Biol Chem: 280:17593-17600.
153. Purohit VS, Balasubramanian SV. Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity. AAPS J 8:E362-370.
154. Gabizon A, Papahadjopoulos D. 1988. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 85:6949-6953.
155. Caselli E, Baricordi OR, Melchiorri L, Bellini F, Ponzin D, Bruni A. 1992. Inhibition of DNA synthesis in peripheral blood mononuclear cells treated with phosphatidylserines containing unsaturated acyl chains. Immunopharmacology 23:205-213.
156. Allen TM, Cullis PR. 2004. Drug delivery systems: Entering the mainstream. Science 303:1818-1822.
157. Stuart DD, Allen TM. 2000. A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim Biophys Acta 1463:219-229.
158. Baru M, Carmel-Goren L, Barenholz Y, Dayan I, Ostropolets S, Slepoy I, Gvirtzer N, Fukson V, Spira J. 2005. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb Haemost 93:1061-1068.
159. Karthik R, Vivek P, Razvan M, Puneet G, Straubinger RM, Balu-Iyer SV. 2008. Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A. J Pharm Sci 97:3753-3764.
160. Powell JS. 2007. Liposomal approach towards the development of a longer-acting factor VIII. Haemophilia 13:23-28.
161. Powell JS, Nugent DJ, Harrison JA, Soni A, Luk A, Stass H, Gorina E. 2008. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost 6:277-283.
162. Peng A, Gaitonde P, Kosloski MP, Miclea RD, Varma P, Balu-Iyer SV. 2009. Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice. J Pharm Sci 98:4480-4484.
163. Rubas W, Supersaxo A, Weder HG, Hartmann HR, Hengartner H, Schott H, Schwendener R. 1986. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int J Cancer 37:149-154.
164. Tseng YC, Mozumdar S, Huang L. 2009. Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev 61:721-731.
165. Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, Skubitz KM, Rivera E, Sparano JA, Dibella NJ, Stewart SJ, Kavanagh JJ, Gabizon AA. 2004. Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials. Semin Oncol 31:53-90.